CytomX Therapeutics, Inc. (NASDAQ:CTMX) will release its fourth-quarter earnings before the opening bell on Monday, March 16.

Analysts expect the South San Francisco, California-based company to report loss of 9 cents per share, versus a year-ago profit of 23 cents per share . The consensus estimate for CytomX Therapeutics' quarterly revenue is $7.33 million (it reported $38.09 million last year), according to Benzinga Pro.

On Nov. 6, CytomX Therapeutics reported worse-than-expected third-quarter financial results.

Shares of CytomX Therapeutics fell 3.9% to close at $4.68 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • Guggenheim analyst Michael Schmidt maintained a Buy rating with a price target of $10 on March 9, 2026. This analyst has an accuracy rate of 82%.
  • Cantor Fitzgerald analyst Olivia Brayer maintained an Overweight rating and raised the price target from $6 to $10 on Feb. 4, 2026. This analyst has an accuracy rate of 61%.
  • Barclays analyst Etzer Darout maintained an Overweight rating and increased the price target from $8 to $10 on Feb. 4, 2026. This analyst has an accuracy rate of 75%.
  • Piper Sandler analyst Joseph Cantanzaro maintained an Overweight rating and boosted the price target from $6.5 to $10 on Jan. 20, 2026. This analyst has an accuracy rate of 60%.
  • HC Wainwright & Co. analyst Mitchell S. Kapoor maintained a Buy rating and raised the price target from $5 to $10 on Nov. 11, 2025. This analyst has an accuracy rate of 65%

Considering buying CTMX stock? Here’s what analysts think:

Photo via Shutterstock